Jill Wechsler

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

The agency proposes significant revisions to oversight programs for drugs and medical products.

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

Amid drug pricing blame game, Congress advancing a range of reform efforts to manage and curb pharmacy benefit manager practices.

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

From supply-chain and clinical-trial disruptions in Ukraine and Russia, to decisions to halt investment or maintain operations, global implications for industry and pharmaceutical production are immense.

Pandemic notwithstanding, the agency maintained a steady pace in 2021 in clearing important new therapies, including new vaccines and drugs for Covid

Biden touts provisions administration believes can curb spending on pharmaceuticals

White House announces official endorsement, paving way for Senate confirmation process

It’s not just innovator pharma companies concerned with the proposed compromise to Medicare price negotiations and inflation-based rebates

Recent FDA actions may finally usher in access boost to follow-on biologics in the US

Plan aims to offset costs associated with proposed social and health initiatives

The drive for “vaccine equity” around the world is strengthening efforts to limit patent protections on innovative drugs and vaccines to combat Covid

Proposal also points to need for further resource investment to “enhance” FDA operations